Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15897465 | 0.96 | ALDH1A1 (0.49) | OPRM1ALDH1A1CYP2C19LMNATSHR | |
| SCHEMBL1510 | 0.90 | OPRM1 (0.58) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL343848 | 0.87 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL4114 | 0.87 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL22992467 | 0.86 | OPRM1 (0.52) | OPRM1ALDH1A1CYP2C19LMNATSHR | |
| SCHEMBL1625409 | 0.86 | OPRM1 (0.67) | OPRM1ALDH1A1CYP2C19LMNATSHR | |
| SCHEMBL14731158 | 0.86 | OPRM1 (0.52) | OPRM1ALDH1A1CYP2C19LMNATSHR | |
| SCHEMBL23005544 | 0.85 | OPRM1 (0.48) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL9899781 | 0.85 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL7807438 | 0.84 | ALDH1A1 (0.51) | OPRM1ALDH1A1CYP2C19LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950676-B1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND APPLICATION THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12595267-B2 | Preparation method for amide compound and application thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12521395-B2 | Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2026-01-13 | — | — | US | disclosed |
| EP-4055015-B1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-04-02 | — | — | EP | disclosed |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-01-05 | — | — | US | disclosed |
| EP-4055015-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2022-09-14 | — | — | EP | disclosed |
| US-20220098178-A1 | Preparation Method for Amide Compound and Application Thereof in Field of Medicine | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3950676-A1 | PREPARATION METHOD FOR AMIDE COMPOUND AND APPLICATION THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950676-A1 | PREPARATION METHOD FOR AMIDE COMPOUND AND APPLICATION THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| CN-113631541-A | Preparation method of amide compound and application of amide compound in field of medicine | 上海华汇拓医药科技有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-2356112-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2356113-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010054764-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054764-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054763-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054763-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595267-B2 | Preparation method for amide compound and application thereof in field of medicine | EZH2, BMI1, EHMT1 | OPRM1 1334/4885ALDH1A1 2473/4885CYP2C19 4296/4885 |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | OPRM1 3642/4885ALDH1A1 604/4885CYP2C19 2278/4885 |
| US-20220098178-A1 | Preparation Method for Amide Compound and Application Thereof in Field of Medicine | EZH2, EZH1, IKZF2 | OPRM1 4412/4885ALDH1A1 2744/4885CYP2C19 4008/4885 |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | IDH1, IDH2, IDH3A | OPRM1 4744/4885ALDH1A1 478/4885CYP2C19 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.